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Abstract
Background: The deposition of unconjugated bilirubin (UCB) in selected regions of the brain
results in irreversible neuronal damage, or Bilirubin Encephalopathy (BE). Although UCB impairs a
large number of cellular functions in other tissues, the basic mechanisms of neurotoxicity have not
yet been fully clarified. While cells can accumulate UCB by passive diffusion, cell protection may
involve multiple mechanisms including the extrusion of the pigment as well as pro-survival
homeostatic responses that are still unknown.
Results: Transcriptome changes induced by UCB exposure in SH-SY5Y neuroblastoma cell line
were examined by high density oligonucleotide microarrays. Two-hundred and thirty genes were
induced after 24 hours. A Gene Ontology (GO) analysis showed that at least 50 genes were directly
involved in the endoplasmic reticulum (ER) stress response. Validation of selected ER stress genes
is shown by quantitative RT-PCR. Analysis of XBP1  splicing and DDIT3/CHOP subcellular
localization is presented.
Conclusion: These results show for the first time that UCB exposure induces ER stress response
as major intracellular homeostasis in surviving neuroblastoma cells in vitro.
Background
The toxic effects of bilirubin, a bile pigment produced dur-
ing the catabolism of heme-containing compounds [1],
have been documented in various biological systems.
Nearly all newborn infants develop increased levels of
unconjugated bilirubin (UCB) in the blood stream, clini-
cally evident as neonatal jaundice [2]. Although this is a
benign and transient phenomenon, abnormal accumula-
tion of bilirubin may cause bilirubin encephalopathy
ranging from minimal neurological injury to severe and
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permanent condition leading to neurodevelopmental
dysfunctions [3]. Furthermore, infants affected by the
genetic pathology of Crigler-Najjar I present high UCB
plasma levels and are particularly exposed to bilirubin
encephalopathy (BE) [4].
The basic mechanisms of hyperbilirubinemia neurotoxic-
ity have not been fully clarified, although it has been
shown that UCB may impair a large number of cellular
functions, including energy metabolism [5], cell prolifer-
ation [6], DNA and protein synthesis [7], receptor func-
tionality [8], and neurotransmitter uptake and release [9].
Furthermore, in the brain UCB seems more injurious to
neurons than to glial cells, with effects that depend on the
cellular subtype [10].
The endoplasmic reticulum (ER) plays a crucial role in the
synthesis and folding of newly secretory and membrane
proteins [11]. Any perturbation that compromises protein
folding and functionality of the ER is referred to as ER
stress. The ER stress response can promote cellular repair
and survival by reducing the load of unfolded proteins
through global attenuation of protein synthesis and by
upregulating chaperones [12]. This response is collectively
termed as the unfolded protein response (UPR) and is
mediated by three ER transmembrane receptors: pancre-
atic ER kinase PERK (also known as eukaryotic translation
initiation factor 2α (eIF2α) kinase 3 (EIF2AK3)), inositol-
requiring enzyme 1 (IRE1) and activating transcription
factor 6 (ATF6).
In resting cells, all of these ER stress receptors are main-
tained in an active state through their association with the
ER chaperone GRP78 (also called BiP). An accumulation
of unfolded proteins causes dissociation of GRP78 from
PERK, IRE1 and ATF6, thereby initiating the UPR. Thus
UPR is a pro-survival response to reduce the accumulation
of unfolded proteins and restore normal function [13].
However, when misfolded-protein aggregation persists
and ER stress cannot be resolved, signalling switches from
a pro-survival to a pro-apoptotic pathway.
Recently, the ER has attracted attention as a key subcellu-
lar compartment in which the effects of several cellular
stresses may contribute to pathological processes culmi-
nating in neuronal injury and degeneration. A central role
of ER dysfunction is evident in various pathologies of the
brain, including acute injuries (transient ischemia,
trauma) and neurodegenerative disorders (Alzheimer's,
Parkinson's and Huntington's diseases) [14].
The present study was designed to analyze the conse-
quences of bilirubin exposure to better understand the
molecular processes underlying neuronal damage and
homeostasis. We used high density oligonucleotide
microarrays to analyze the gene expression profile of
human neuroblastoma SH-SY5Y cells upon UCB treat-
ment. Gene expression data and experimental validation
point to ER stress as the major intracellular homeostatic
response in surviving cells.
Results
Characterization of the cell viability of UCB treated SH-
SY5Y cells
The human neuroblastoma SH-SY5Y cell line is a well-
established in vitro cellular model to study the biological
consequences of neuroactive molecules, drugs and toxins.
To assess UCB effects, we have taken advantage of previ-
ous studies where the outcome of clinically relevant UCB
concentrations was tested and the cytotoxic effects
revealed [15,16]. The sensitivity of SH-SY5Y cells to UCB
treatment was thus evaluated by measuring cell viability
after exposing cells to a concentration of free bilirubin of
140 nM (Bf 140 nM) for 1, 4 and 24 h. As shown in Figure
1, cell viability was reduced to 60% already after 1 h of
UCB treatment and the extent of reduction in cell viability
never exceeded the 40% of the cell population, even with
longer treatments.
Gene expression analysis by oligonucleotide arrays in UCB 
treated SH-SY5Y cells
To examine the molecular events associated with the
homeostatic response to UCB treatment, high density oli-
gonucleotide microarrays (Affymetrix GeneChip Human
U133A 2.0) were used to interrogate the expression of
over 14,500 transcripts. RNA was isolated from SH-SY5Y
neuroblastoma cells treated with Bf 140 nM for 1, 4 and
24 h. Experiments were performed in three biological rep-
licates with control samples monitoring the effects of
DMSO used as Bf solvent.
Analysis of the microarray hybridization data, as reported
in Methods, produced a list of 258 probe sets with a false
discovery rate (FDR) of 10%. This list corresponded to
230 genes upregulated after 24 h of UCB treatment ("late
response"). No down-regulated genes were detected. The
fold change of transcript levels ranged from 1.2 to 6.9, the
majority of which being toward the lower end. A list of all
differentially expressed genes is provided in the Addi-
tional file 1. No significant changes of gene expression
were observed after 1 and 4 h of UCB treatment ("early
response"). We obtained a list of 58 probe sets when a
FDR of 0% was applied and a list of 196 probe sets with a
FDR of 5%. Furthermore, 400 probe sets were induced
with a FDR of 20% with no down-regulated genes (data
not shown).BMC Genomics 2009, 10:543 http://www.biomedcentral.com/1471-2164/10/543
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Differentially expressed genes were then examined for
their Gene Ontology (GO) annotations concerning their
cellular localization. As shown in Table 1 and as detailed
in the Additional file 2, the analysis revealed that these
genes were mainly distributed in the endoplasmic reticu-
lum (ER), the Golgi apparatus (Golgi) and in the nucleus.
To obtain insights into the pathways in which they were
mainly involved, genes were sorted into distinct func-
tional subgroups. UCB treatment induced genes belong-
ing to functional categories related to the UPR in the
protein secretory pathway (Table 2) as well as to regula-
tion of transcription and DNA-dependent processes
(Table 3). A set of up-regulated genes included plasma
membrane transporters of the family of the solute carrier
transporters (SLCs) and other genes involved in amino
acid metabolism (Table 4). In the remaining part of the
manuscript the attention will be focused on the UPR and
ER stress responses, since the majority of up-regulated
genes are well known members of these homeostatic
pathways.
UCB treatment induced expression of ER stress genes in 
the UPR of the secretory pathway
UPR serves many aspects of the secretory pathway and is
predominantly involved in the response to stress condi-
tions when proteins are misfolded. GO categories of UPR
components induced by UCB are shown in Table 2. These
include stress sensing and signalling, protein folding,
translocation, vesicular transport and ER-associated deg-
radation. Genes known or predicted by sequence homol-
ogy to play a physiological role in secretion or in the
biogenesis of organelles were also increased.
The largest group of up-regulated genes was represented
by ER-resident molecular chaperone and oxido-reductase
proteins. Among the molecular chaperones, we found
established UPR target genes such as HSPA5 (heat shock
70 kDa protein 5) (upregulated 2.3 times), known also as
GRP78 (glucose-regulated protein, 78 kDa) or BiP [17],
HSP90B (heat shock protein 90 kDa beta (Grp94) (1.5),
member 1), DNAJB9 (4.4) and DNAJC10 (1.8)[18]. Addi-
tional genes included PDIA5  (1.7),  PDIA6  (1.5) and
ERO1LB (2.1) that are involved in oxidative protein fold-
ing [19].
A second major group was composed by genes involved in
co-translational translocation of proteins across the ER
membrane, to the Golgi and in the anterograde/retro-
grade transport back into the cytosol. The group included
the signal sequence receptor SSR1 (1.6), the translocating
Cell viability in SH-SY5Y cells treated with UCB Figure 1
Cell viability in SH-SY5Y cells treated with UCB. SHSY5Y were exposed to UCB treatment at Bf 140 nM during a time 
course of 1, 4 and 24 hours and cell viability was evaluated by MTT assay. Cell viability of UCB-treated samples was expressed 
as a percentage of the respective samples treated with DMSO 0.6%. Data are expressed as the mean ± SD of 3 independent 
experiments performed in triplicate.
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Table 1: Identification of the cellular localization of differentially 
expressed genes in response to 24 h of UCB treatment at Bf 140 
nM in SH-SY5Y cells.
Localization Number of genes %
Endoplasmic reticulum 47 25.54
Golgi apparatus 25 13.59
Nucleus 41 22.28
The table shows the number and percentage (%) of the 217 total 
genes that were recognized as valid gene names in the 
gene_association.goa_human_hgnc file according to GO slim terms 
from the cellular ontology in regard to Endoplasmic reticulum, Golgi 
apparatus and nucleus localization. All details are reported in Table S2 
in the Additional file 2.BMC Genomics 2009, 10:543 http://www.biomedcentral.com/1471-2164/10/543
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Table 2: Differentially expressed genes involved in ER stress signalling and UPR in response to UCB treatment in SH-SY5Y cells.
Probe_Id Gene_Name Gene_Symbol FC Location
Stress sensing and signalling
218696_at eukaryotic translation initiation factor 2-alpha kinase 3 EIF2AK3 2.2 ER membrane
Folding (Chaperones and oxidoreductase)
200068_s_at Calnexin CANX 1.5 ER membrane; cell surface
202843_at DnaJ (Hsp40) homolog, subfamily B, member 9 DNAJB9 4.4 ER lumen
202842_s_at DnaJ (Hsp40) homolog, subfamily B, member 9 DNAJB9 4.0 ER lumen
221782_at DnaJ (Hsp40) homolog, subfamily C, member 10 DNAJC10 1.8 ER lumen
220012_at ERO1-like beta (S. cerevisiae) ERO1LB 2.1 ER; ER membrane
210627_s_at glucosidase I GCS1 1.5 ER lumen
200599_s_at heat shock protein 90 kDa beta (Grp94), member 1 HSP90B1 1.5 ER lumen; cell surface
211936_at heat shock 70 kDa protein 5 
(glucose-regulated protein, 78 kDa)
HSPA5 2.3 ER lumen; cell surface
200825_s_at hypoxia up-regulated 1 HYOU1 2.2 ER; ER lumen
203857_s_at protein disulfide isomerase family A, member 5 PDIA5 1.7 ER; ER lumen
208639_x_at protein disulfide isomerase family A, member 6 PDIA6 1.5 ER; ER lumen
207668_x_at protein disulfide isomerase family A, member 6 PDIA6 1.4 ER; ER lumen
217716_s_at Sec61 alpha 1 subunit (S. cerevisiae) SEC61A1 1.6 ER membrane
219499_at Sec61 alpha 2 subunit (S. cerevisiae) SEC61A2 1.4 ER membrane
201916_s_at SEC63 homolog (S. cerevisiae) SEC63 1.5 ER membrane
Vesicle-mediated transport
202710_at BET1 homolog (S. cerevisiae) BET1 1.6 ER; Golgi;membrane
204017_at KDEL (Lys-Asp-Glu-Leu) endoplasmic reticulum protein 
retention receptor 3/ERD2L3
KDELR3 1.6 ER; ER membrane
207264_at KDEL (Lys-Asp-Glu-Leu) endoplasmic reticulum protein 
retention receptor 3
KDELR3 1.3 ER; ER membrane
212245_at multiple coagulation factor deficiency 2 MCFD2 1.5 ER-Golgi intermediate compartment; Golgi; ERBMC Genomics 2009, 10:543 http://www.biomedcentral.com/1471-2164/10/543
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chain-associating membrane protein TRAM1 (1.8), mem-
bers of the SEC61 complex, such as SEC61A1  (1.6),
SEC61A2 (1.4) and SEC63 (1.5), and SERP1 (Stress-asso-
ciated Endoplasmic Reticulum Protein 1) (1.9), also
known as RAMP4 (Ribosome-Associated Membrane Pro-
tein 4), that is a Sec61-associated polypeptide specifically
induced by ER stress [20]. Up-regulated genes were also
represented by the coated vesicle membrane proteins,
such as SEC23B (1.8), SEC24D (2.1), SEC31A (1.6) and
SCFD1 (1.5), as well as by the transmembrane trafficking
proteins TMED2 (1.4), TMED9 (1.6) and TMED10 (1.4).
The ER-associated degradation (ERAD) system eliminates
misfolded proteins by their retrotranslocation across the
ER membrane into the cytosol, where ubiquitin-conjugat-
ing enzymes target them for proteosomal degradation.
ERAD requires a number of dedicated ER-resident factors.
Indeed, HERPUD1 or HERP (Homocysteine-induced ER
215548_s_at sec1 family domain containing 1 SCFD1 1.5 Golgi; ER; ER membrane; nucleus
201583_s_at Sec23 homolog B (S. cerevisiae) SEC23B 1.8 COPII vesicle coat; ER; Golgi
210293_s_at Sec23 homolog B (S. cerevisiae) SEC23B 1.6 COPII vesicle coat; ER; Golgi
202375_at SEC24 related gene family, member D (S. cerevisiae) SEC24D 2.1 COPII vesicle coat; ER; Golgi
215209_at SEC24 related gene family, member D (S. cerevisiae) SEC24D 1.6 COPII vesicle coat; ER; Golgi
200945_s_at SEC31 homolog A (S. cerevisiae) SEC31A 1.6 COPII vesicle coat; ER
200970_s_at stress-associated endoplasmic reticulum protein 1 SERP1 1.9 ER; membrane
200971_s_at stress-associated endoplasmic reticulum protein 1 SERP1 1.7 ER; membrane
200891_s_at signal sequence receptor, alpha 
(translocon-associated protein alpha)
SSR1 1.6 ER; membrane
200087_s_at transmembrane emp24 domain trafficking protein 2 TMED2 1.4 Golgi; ER-Golgi intermediate compartment
208757_at transmembrane emp24 protein transport domain 
containing 9
TMED9 1.6 ER; ER membrane
212352_s_at transmembrane emp24-like trafficking protein 10 (yeast) TMED10 1.4 Golgi; ER-Golgi intermediate compartment
201398_s_at translocation associated membrane protein 1 TRAM1 1.8 ER; membrane
Degradation
218333_at Der1-like domain family, member 2 DERL2 1.6 ER membrane
203279_at ER degradation enhancer, mannosidase alpha-like 1 EDEM1 2.1 ER lumen membrane
217168_s_at homocysteine-inducible, endoplasmic reticulum stress-
inducible, ubiquitin-like domain member 1
HERPUD1 4.1 ER membrane
202061_s_at sel-1 suppressor of lin-12-like (C. elegans) SEL1L 2.1 ER membrane
Genes are sub-categorized according to their GO Biological Process annotation. Fold changes (FC) are fold differences for cells treated with Bf 140 
nM versus cells grown in DMSO 0.6% (controls) for 24 h. Affymetrix Probe Set-IDs, gene names and symbol, fold change (FC), and cellular location 
are indicated.
Table 2: Differentially expressed genes involved in ER stress signalling and UPR in response to UCB treatment in SH-SY5Y cells. (Continued)BMC Genomics 2009, 10:543 http://www.biomedcentral.com/1471-2164/10/543
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Table 3: Differential expression of genes mapping to "regulation of transcription, DNA-dependent" (GO Biological Process) in 
response to UCB treatment in SH-SY5Y cells.
Probe_Id Gene_Name Gene_Symbol FC Location
202672_s_at activating transcription factor 3 ATF3 4.9 nucleus; nucleolus
200779_at activating transcription factor 4 
(tax-responsive enhancer element B67)
ATF4 1.7 nucleus; cytoplasm; plasma membrane
204998_s_at activating transcription factor 5 ATF5 1.6 nucleus; cytoplasm
204999_s_at activating transcription factor 5 ATF5 1.5 nucleus; cytoplasm
212501_at CCAAT/enhancer binding protein (C/EBP), beta CEBPB 4.9 nucleus; cytoplasm
204203_at CCAAT/enhancer binding protein (C/EBP), gamma CEBPG 2.4 Nucleus
212345_s_at cAMP responsive element binding protein 3-like 2 CREB3L2 1.7 ER; ER membrane; integral to membrane; 
nucleus
207630_s_at cAMP responsive element modulator CREM 3.1 Golgi apparatus; cytoplasm; nucleus; 
transcription factor complex
209967_s_at cAMP responsive element modulator CREM 2.9 Golgi apparatus; cytoplasm; nucleus; 
transcription factor complex
214508_x_at cAMP responsive element modulator CREM 2.7 Golgi apparatus; cytoplasm; nucleus; 
transcription factor complex
209674_at cryptochrome 1 (photolyase-like) CRY1 1.4 Cytoplasm; mitochondrion; nucleus
209383_at DNA-damage-inducible transcript 3 DDIT3 6.7 Nucleus
219551_at ELL associated factor 2 EAF2 1.4 nucleus; nuclear speck
208436_s_at interferon regulatory factor 7 IRF7 1.7 Cytoplasm; nucleus
201466_s_at jun oncogene JUN 3.5 cytosol; nuclear chromosome; nucleus; TF 
complex
201464_x_at jun oncogene JUN 2.8 cytosol; nuclear chromosome; nucleus; TF 
complex
203752_s_at jun D proto-oncogene JUND 1.6 Chromatin; nucleus
208961_s_at Kruppel-like factor 6 KLF6 1.8 cellular component; cytoplasm; intracellular; 
nucleus
204970_s_at v-maf musculoaponeurotic fibrosarcoma oncogene 
homolog G (avian)
MAFG 1.5 Nucleus
213696_s_at mediator of RNA polymerase II transcription, subunit 8 
homolog (S. cerevisiae)
MED8 1.6 mediator complex; nucleus
212803_at NGFI-A binding protein 2 (EGR1 binding protein 2) NAB2 1.5 Nucleus
203574_at nuclear factor, interleukin 3 regulated NFIL3 2.4 Nucleus
221803_s_at nuclear receptor binding factor 2 NRBF2 1.3 Cytoplasm; nucleusBMC Genomics 2009, 10:543 http://www.biomedcentral.com/1471-2164/10/543
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Protein) (4.1) [21] was significantly induced as well as
EDEM1 (ER Degradation Enhancer Mannosidase alpha-
like 1) (2.1) [22], SEL1L (2.1), a transmembrane cofactor
of the E3 ubiquitin ligase HRD1 [23], and DERL2 (Derlin
membrane-like domain family member 2) (1.6) whose
product associates with EDEM1 and is a specific target of
the IRE1 branch of the UPR response [24].
UCB treatment induced expression of proteins relevant in 
the regulation of transcription during ER stress response
As shown in Table 3, several differentially expressed genes
were classified into the GO category of "regulation of tran-
scription, DNA-dependent". Up-regulated transcription
factors included two established UPR target genes: DDIT3
(6.7), also known as CHOP or C/EBP homologous pro-
tein, and XBP1, X box-binding protein 1 (2.6). CHOP is a
29-kDa leucine zipper transcription factor that is ubiqui-
tously expressed at a low level and robustly up-regulated
in response to various stress conditions [25]. CHOP is
proapoptotic and a key mediator of ER stress-induced cell
death [26,27]. XBP1 gene, after a nonconventional splic-
ing event [28], codes for a transcription activator that reg-
ulates a subset of ER-resident chaperones that are essential
for protein folding, maturation and degradation in the ER
[29]. Additional stress-responsive transcriptional regula-
tors induced by UCB included ATF3 (4.9), ATF4 (1.7),
ATF5 (1.6), CEBPB (4.9), CEBPG (2.4), JUN (3.5) and
JUND (1.6). Interestingly, although ATF4 showed a mod-
erate induction, several of its downstream targets were
strongly up-regulated, e.g. DDIT3, ATF3, CEBPB, CEBPG,
CREB3L2 (1.7) and TRIB3 (6.7). TRIB3 (also known as
NIPK, SKIP3, TRB3 and SINK) is an ER stress-inducible
gene that is involved in CHOP-dependent cell death as a
second messenger during ER stress [30].
UCB treatment induced expression of genes involved in 
protein synthesis/translation, autophagy and aminoacid 
transport/metabolism
The translational machinery for a new boost of protein
synthesis has been suggested to be amplified during UPR-
associated translational attenuation [13,31]. As shown in
Table 4, we observed an up-regulation of 6 tRNA syn-
thetase genes, such as AARS  (1.7),  CARS  (1.8),  GARS
(1.8), MARS (1.5), SARS (2.2) and WARS (2.9), which are
involved in tRNA processing. We also observed the induc-
tion of 2 eukaryotic translation initiation factors, that are
EIF1 (1.4) and EIF5 (1.6). One of the stronger up-regu-
lated genes was FAM129A (family with sequence similar-
ity 129, member A) (6.9), also known as NIBAN, which
has been recently demonstrated to be involved in the ER
202861_at period homolog 1 (Drosophila) PER1 1.7 Cytoplasm; nucleus
36829_at period homolog 1 (Drosophila) PER1 1.6 Cytoplasm; nucleus
217861_s_at prolactin regulatory element binding PREB 1.9 ER; membrane; nucleus
202148_s_at pyrroline-5-carboxylate reductase 1 PYCR1 1.5 mitochondrion
215670_s_at SCAN domain containing 2 SCAND2 1.4 Nucleus
201471_s_at sequestosome 1 SQSTM1 2.4 cytoplasm; cytosol; late endosome; nucleus
208991_at signal transducer and activator of transcription 3 
(acute-phase response factor)
STAT3 1.4 Cytoplasm; nucleus
213024_at TATA element modulatory factor 1 TMF1 1.8 Golgi apparatus
218145_at tribbles homolog 3 (Drosophila) TRIB3 6.7 Nucleus
208763_s_at TSC22 domain family, member 3 TSC22D3 1.6 Nucleus
218012_at TSPY-like 2 TSPYL2 1.9 Cytoplasm; nucleolus; nucleus
200670_at X-box binding protein 1 XBP1 2.6 Nucleus
207219_at zinc finger protein 643 ZNF643 1.4 intracellular; membrane; nucleus
Fold changes (FC) are fold differences for cells treated with Bf 140 nM versus cells grown in DMSO 0.6% (controls) for 24 h. Affymetrix Probe Set-
IDs, gene names and symbol, fold change (FC), and cellular location are indicated.
Table 3: Differential expression of genes mapping to "regulation of transcription, DNA-dependent" (GO Biological Process) in 
response to UCB treatment in SH-SY5Y cells. (Continued)BMC Genomics 2009, 10:543 http://www.biomedcentral.com/1471-2164/10/543
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Table 4: Differential expression of genes involved in protein synthesis/translation, amino acid metabolism/transport and autophagy in 
response to UCB treatment in SH-SY5Y cells.
Probe_Id Gene_Name Gene_Symbol FC Location Function
Protein synthesis/translation
201000_at alanyl-tRNA synthetase AARS 1.7 cytoplasm tRNA aminoacylation
202402_s_at cysteinyl-tRNA synthetase CARS 1.8 cytoplasm tRNA aminoacylation
202021_x_at eukaryotic translation initiation factor 1 EIF1 1.4 cytoplasm translation initiation factory 
activity
208290_s_at eukaryotic translation initiation factor 5 EIF5 1.6 cytoplasm translation initiation factory 
activity
208708_x_at eukaryotic translation initiation factor 5 EIF5 1.5 cytoplasm translation initiation factory 
activity
208693_s_at glycyl-tRNA synthetase GARS 1.8 cytoplasm tRNA aminoacylation
213671_s_at methionyl-tRNA synthetase MARS 1.5 cytoplasm tRNA aminoacylation
201475_x_at methionyl-tRNA synthetase MARS 1.5 cytoplasm tRNA aminoacylation
213672_at methionyl-tRNA synthetase MARS 1.4 cytoplasm tRNA aminoacylation
200802_at seryl-tRNA synthetase SARS 2.2 cytoplasm tRNA aminoacylation
200629_at tryptophanyl-tRNA synthetase WARS 2.9 cytoplasm tRNA aminoacylation
200628_s_at tryptophanyl-tRNA synthetase WARS 2.5 cytoplasm tRNA aminoacylation
mTOR pathway and autophagy
217967_s_at family with sequence similarity 129, member A FAM129A 6.9 cytoplasm not defined
217966_s_at family with sequence similarity 129, member A FAM129A 4.0 cytoplasm not defined
202887_s_at DNA-damage-inducible transcript 4 DDIT4 4.4 cytoplasm not defined
208869_s_at GABA(A) receptor-associated protein like 1 GABARAPL1 1.9 Golgi; ER; cytoplasm protein binding
211458_s_at GABA(A) receptors associated protein like 3 GABARAPL3 2.3 microtubule protein binding
203827_at WD repeat domain, phosphoinositide interacting 1 WIPI1 2.8 Golgi; autophagic 
vacuole membrane; 
cytoplasm
receptor binding
213836_s_at WD repeat domain, phosphoinositide interacting 1 WIPI1 2.7 Golgi; autophagic 
vacuole membrane; 
cytoplasm
receptor bindingBMC Genomics 2009, 10:543 http://www.biomedcentral.com/1471-2164/10/543
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stress response and to positively affect the protein transla-
tion machinery by regulating the mTOR pathway [32].
Interestingly, the list of genes induced during UCB treat-
ment also includes DDIT4 (DNA-Damage-Inducible Tran-
script 4) (4.4), also known as REDD1/RTP801/Dig2, that
is another well-known regulator of the mTOR pathway
[33]. The mTOR-dependent pathway is strongly con-
nected to the autophagic machinery, and indeed
autophagy-related genes such as GABARAPL1 (GABA(A)
receptor-associated protein like 1 or ATG8) (1.9),
GABARAPL3 (GABA(A) receptors-associated protein like 3
(pseudogene)) (2.3) and WIPI1  (WD repeat domain,
phosphoinositide interacting 1 gene or Atg18) (2.8) were
also positively differentially expressed, suggesting that
surviving neuroblastoma cells may present an induction
of autophagy [34,35].
UCB exposure also activated genes involved in amino acid
metabolism (Table 4). Among the strongest up-regulated
genes, SLC7A11 (6.8) and SLC3A2 (3.8) were identified.
These two genes encode respectively for xCT, the light
chain subunit, and for 4F2hC, the glycosylated heavy-
chain subunit, that are components of the system xCT,
anionic amino acid transport system specific for cystine
and glutamate [36]. Recently, the UCB-induced SLC7A5
(3.2) has been shown to physically and functionally inter-
act with SLC3A2, forming a bidirectional amino acid
transporter and representing a key regulator of both the
mTOR pathway and autophagy [37].
Amino acid metabolism/transport
217678_at solute carrier family 7, (cationic amino acid 
transporter, y+ system) member 11
SLC7A11 6.8 membrane amino acid transport
209921_at solute carrier family 7, (cationic amino acid 
transporter, y+ system) member 11
SLC7A11 6.6 membrane amino acid transport
201195_s_at solute carrier family 7 (cationic amino acid 
transporter, y+ system), member 5
SLC7A5 3.2 membrane amino acid transport
200924_s_at solute carrier family 3 (activators of dibasic and 
neutral amino acid transport), member 2
SLC3A2 3.8 membrane amino acid transport
209610_s_at solute carrier family 1 (glutamate/neutral amino 
acid transporter), member 4
SLC1A4 2.3 membrane amino acid transport
212810_s_at solute carrier family 1 (glutamate/neutral amino 
acid transporter), member 4
SLC1A4 2.1 membrane amino acid transport
212811_x_at solute carrier family 1 (glutamate/neutral amino 
acid transporter), member 4
SLC1A4 2.1 membrane amino acid transport
212110_at solute carrier family 39 (zinc transporter), 
member 14
SLC39A14 1.6 membrane zinc ion transport
203165_s_at solute carrier family 33 (acetyl-CoA transporter), 
member 1
SLC33A1 2.2 ER; membrane acetyl-CoA transporter 
activity
203164_at solute carrier family 33 (acetyl-CoA transporter), 
member 1
SLC33A1 1.9 ER; membrane acetyl-CoA transporter 
activity
202433_at solute carrier family 35, member B1 SLC35B1 1.6 ER; membrane carbohydrate transport
221024_s_at solute carrier family 2 (facilitated glucose 
transporter), member 10
SLC2A10 1.6 membrane glucose transport
Genes are sub-categorized according to their GO Biological Process annotation. Fold changes (FC) are fold differences for cells treated with Bf 140 
nM versus cells grown in DMSO 0.6% (controls) for 24 h. Affymetrix Probe Set-IDs, gene names and symbol, fold change (FC), cellular location are 
indicated.
Table 4: Differential expression of genes involved in protein synthesis/translation, amino acid metabolism/transport and autophagy in 
response to UCB treatment in SH-SY5Y cells. (Continued)BMC Genomics 2009, 10:543 http://www.biomedcentral.com/1471-2164/10/543
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Validation of selected genes by quantitative RT-PCR (qRT-
PCR)
For validation, we selected genes considered of interest
based on their involvement in ER stress response. Gene
expression levels of DDIT3,  HSPA5,  XBP1,  HERPUD1,
TRIB3, FAM129A and SLC7A11 were verified by qRT-PCR.
Results are reported in Figure 2. The fold differences deter-
mined by qRT-PCR were very similar to those obtained by
the high density oligonucleotide microarray gene expres-
sion analysis.
Analysis of XBP1 splicing and DDIT3/CHOP subcellular 
localization in UCB treated SH-SY5Y cells
We investigated two independent events that are known
activators of the ER stress transcriptional program: uncon-
ventional splicing of XBP1 and cytoplasm/nuclear shut-
tling of DDIT3/CHOP. The splicing of XBP1  transcript
changes its open reading frame to code for a transcription
factor (spliced XBP1 or sXBP1) that activates the expres-
sion of a subset of ER stress/UPR related genes [28,29].
Here we show that UCB treatment is indeed able to trigger
this unconventional splicing (Figure 3A). The nuclear
localization of the transcription factor DDIT3/CHOP [25]
is one of the most commonly used indicators of ER stress.
As presented in Figure 3B, we observed a diffuse cytoplas-
mic localization in untreated and DMSO 0.6% control
cells, but a major nuclear staining in cells treated with Bf
140 nM. This indicates activation of a CHOP-dependent
transcriptional program. These data represent an inde-
pendent proof of the induction of a vigorous ER stress.
Discussion
Bilirubin encephalopathy is one of the consequences of
severe hyperbilirubinemia and is characterized by multi-
focal deposition of UCB in selected regions of the brain,
resulting in temporary or permanent impairment of audi-
tory, motor or mental functions [38]. Cellular UCB level
is closely related to the free concentration (Bf) of the pig-
ment in plasma and to the mechanisms regulating the
traffic of UCB among plasma, cerebral spinal fluid and
cells. Although UCB is formed in virtually all cells and
may enter by passive diffusion [39], intracellular concen-
tration is determined by cellular export and metabolic
transformation of the pigment. Interestingly, only certain
neuronal cell types present a UCB susceptibility to
undergo necrosis and apoptosis [40], whereas astrocytes
are relatively spared. This has been linked to a higher con-
tent of MRP1, a transporter with high affinity to UCB [41]
able to keep the intracellular UCB concentration low.
Importantly, the level of MRP1 expression in human neu-
Analysis of gene expression related to the ER stress response Figure 2
Analysis of gene expression related to the ER stress response. Gene expression levels of selected genes (X axis) were 
analyzed by qRT-PCR. Y axis represents the gene expression level normalized to housekeeping genes (GAPDH and β-actin) of 
SH-SY5Y cells not treated (untreated) or treated with vehicle (DMSO 0.6%) or UCB (Bf 140 nM) for 24 hours. These results 
represent at least three RNA samples per experimental condition run in triplicate.
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roblastoma SH-SY5Y cells is inversely and linearly corre-
lated with UCB toxic effects [16].
The molecular mechanisms of intracellular UCB toxicity
are still unclear [42]. UCB has been initially proved to be
a pro-apoptotic agent, suppressing cell growth by induc-
ing DNA fragmentation, mitochondrial release of cyto-
chrome c, activation of caspase-3 and cleavage of
poly(ADP)ribose polymerase [40]. More recently, oxida-
tive stress has emerged as a potential crucial event, since
its generation mirrors UCB-mediated apoptosis [43,44].
In various cellular systems, UCB causes reactive oxygen
species (ROS) production, protein oxidation, lipid perox-
idation and disruption of glutathione metabolism [43,45-
47]. Furthermore, UCB-mediated oxidative stress is also in
part responsible for inhibition of cell growth [48,49].
Inhibition of cell proliferation has been indeed observed
in primary vascular smooth muscle cells in vitro as well as
inferred by gene expression data on the repression of cell
cycle-related genes in the liver of a mouse model of Cri-
gler-Najjar type I disease [50]. To study the effects of intra-
cellular UCB on neurons, we took advantage of the
human neuroblastoma SH-SY5Y cell line. These cells have
been widely used in neurobiology as the in vitro system of
choice to dissect molecular pathways leading to neurode-
generation. Previous studies have already shown that neu-
roblastoma cells are a good in vitro model to address the
consequences of clinically relevant UCB concentrations
[16]. Although we are aware of the limitations in the use
of a neuroblastoma cell line to recapitulate dysfunctions
that occur in neonatal human brain, this experimental
model allowed us to dissect in details the molecular
events elicited by UCB.
Treatment with Bf 140 nM was highly toxic, triggering
death in 40% of the cells within one hour. This is expected
since the accepted threshold for bilirubin toxicity approx-
imately occurs at 70 nM [5]. 63% reduction in cell viabil-
ity at 4 h after bilirubin exposure were previously
demonstrated in the rat neuroblastoma N-115 cell line
[7]. Furthermore, Silva RF et al. [51] showed 85 nM Bf trig-
gered deleterious effects on mitochondrial function.
A full understanding of molecular mechanisms of cell
death will require additional investigation. UCB has been
Analysis of XBP1 splicing and DDIT3/CHOP subcellular localization in SH-SY5Y cells treated with UCB Figure 3
Analysis of XBP1 splicing and DDIT3/CHOP subcellular localization in SH-SY5Y cells treated with UCB. (A) 
mRNA levels of the spliced form of XBP1 (s - spliced, u - unspliced), indicator of ER stress, were examined by RT-PCR after 24 
h of treatment. The amplified products were separated on a 2% agarose gel and visualized with ethidium bromide staining. Data 
are representative of n ≥ 2 separate experiments per condition point. (B) The expression of CHOP (shown in red) was exam-
ined with immunocytochemistry as described in Methods. Representative images are shown for SH-SY5Y cells not treated 
(untreated) or treated with vehicle (DMSO 0.6%) or UCB (Bf 140 nM). The nuclei (shown in blue) were visualized with DAPI 
staining. Bar = 10 μm.
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previously proved to induce apoptosis in neuroblastoma
cells, although necrosis could not be excluded [52].
Furthermore, the criteria to distinguish sensitive from
insensitive neuroblastoma cells remain unclear. One may
speculate that subtle heterogeneity in the level of differen-
tiation may play a role in susceptibility to insults. Alterna-
tively, cell death induction may depend on cell cycle
position.
We then focused on the 60% of surviving cells to test the
hypothesis that these neurons may express a homeostatic
response.
A gene expression approach was carried out to identify
gene expression patterns and signalling pathways induced
upon UCB treatment. No significant changes of gene
expression were observed after 1 and 4 h of UCB treat-
ment. After 24 h, 230 genes were induced while no down-
regulated genes were observed even when an FDR of 20%
was applied.
The lack of an "early response" is surprising since it fails to
provide a potential mechanism for cell survival within the
first hour. Therefore, present data suggest that it is very
unlikely that the molecular pathways induced at 24 hours
play a role in the survival of cells after one hour of treat-
ment.
GO analysis of the "late response" genes proved for the
first time that UCB treatment induces an ER stress
response in neuroblastoma cells in vitro. Evidences for ER
stress involvement are overwhelming. Among others,
genes induced by UCB treatment include several molecu-
lar chaperones like BiP, a well-known marker of ER over-
load, as well as molecular components of the ERAD
system, that has been recently positioned in a central stage
among the molecular mechanisms of neurodegeneration
[53,54]. Furthermore, two well-known events in ER stress,
such as XBP1 unconventional splicing and DDIT3/CHOP
nuclear relocation, were proved to be triggered by UCB
treatment, therefore providing additional experimental
evidences.
UCB also altered several components of the translational
machinery including tRNA synthesis genes and transla-
tion initiation factors. The translation machinery is con-
sidered one of the major targets of the ER stress response
to regulate protein synthesis and decrease protein over-
load. Since no data are available in literature about the
relationship between UCB intracellular concentration and
translation rate, there is a compelling need for an accurate
proteomic analysis of UCB effects in SH-SY5Y neuroblas-
toma cells. A complementary cellular strategy in ER stress
conditions includes an increase in protein degradation. In
this context some UCB-induced genes suggested a role for
autophagy. It is of notice that autophagy has been recently
associated with neurodegenerative diseases as well as with
inhibition of cell growth and entering into a quiescent
state [55,56]. This may correlate to previous reports show-
ing a severe inhibition of cell proliferation mediated by
UCB [49]. Further experimental validation is needed to
prove an increase of autophagy.
Finally, the induction of both subunits of the transport
system X(C)(-) was also observed: SLC3A2 (4F2hc) and
SLC7A11 (xCT) are able to heterodimerize to mediate cys-
tine-glutamate exchange and regulate intracellular glu-
tathione levels. Since the maintenance of a high
glutathione concentration may be protective [57], we
speculate that induction of the X(C)(-) transport system
may represent a major pro-survival response, as has been
recently shown in neurons [58]. Interestingly, we could
not observe any significant differential gene expression of
MRP1 at any point of the time course suggesting that this
transporter plays a negligible role in UCB-induced adap-
tation in this in vitro model.
Conclusion
In summary, the present study shows for the first time that
intracellular accumulation of UCB in surviving neuroblas-
toma SH-SY5Y cell line provokes ER stress.
Methods
Chemicals
UCB was purchased from Sigma (St. Louis, MO, USA) and
purified as described by McDonagh and Assisi [59]. UCB
was dissolved in 0.6% v/v of DMSO and diluted in 100 μL
of complete medium supplemented with 15% Fetal
Bovine Serum containing 54 μM albumin. Bf concentra-
tion was 140 nM, measured as described previously [60].
3(4,5-dimethylthiazolyl-2)-2,5 diphenyl tetrazolium
(MTT), HPLC-grade dimethyl sulfoxide (DMSO), and all
other chemicals were purchased from Sigma, unless oth-
erwise specified.
Experimental treatment of SH-SY5Y cell line
SH-SY5Y human neuroblastoma cells (ATCC CRL-2266)
were cultured in a humidified incubator at 37°C and 5%
CO2 in F12-EMEM (1:1) containing 15% foetal bovine
serum (FBS), 2 mM L-glutamine, 25 μg/mL gentamicin,
100 U/ml penicillin, and 100 μg/mL streptomycin at
37°C with 5% CO2. Cells were seeded at 6 × 106 cells in
75 cm2 flasks and grown for 24 h (cells reached 70-80%
confluence). The medium was then replaced with experi-
mental medium, which was either free medium
(untreated samples) or 140 nM Bf medium (Bf 140 nM
samples), or 0.6% DMSO medium (DMSO 0.6% sam-BMC Genomics 2009, 10:543 http://www.biomedcentral.com/1471-2164/10/543
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ples) and cells were allowed to grow. After 1, 4 and 24 h
cells were collected and processed for cell viability (MTT
cell viability assay), microarray, quantitative RT-PCR and
immunofluorescence analyses. Separate flasks of cells
were used for each of the treatments and assays. Experi-
ments were performed at least in three independent bio-
logical replicates at all time points.
MTT cell viability assay
Cells were treated as described above and the MTT cell via-
bility assay was performed as previously described by
Denizot and Lang [61]. Absorbance was measured at 562
nm using a microtiter plate reader (LC 400, Beckman
Coulter, Milan, Italy). Cell viability of UCB treated sam-
ples was expressed as a percentage of the respective sam-
ples treated with DMSO alone.
RNA extraction and quantitative RT-PCR (qRT-PCR)
Total RNA was isolated using the TRIzol reagent (Invitro-
gen) following the manufacturer's instructions. Single
strand cDNA was obtained from 1 μg of purified RNA
using the iSCRIPT™ cDNA Synthesis Kit (Bio-Rad) accord-
ing to manufacturer's instructions. Quantitative RT-PCR
was performed using SYBR-Green PCR Master Mix
(Applied Biosystem) and an iCycler IQ Real Time PCR
System (Bio-Rad). Sequence of gene specific primers used
for qRT-PCR is provided in Table 5. Expression of the gene
of interest was normalized to house keeping genes (glyc-
eraldehyde-3-phosphate dehydrogenase or GAPDH and
β-actin) and the initial amount of the template of each
sample was determined as relative expression versus one
of the samples chosen as reference. The relative expression
of each sample was calculated by the formula 2 exp-ΔΔCt
(User Bulletin 2 of the ABI Prism 7700 Sequence Detec-
tion System). GAPDH  and  β-actin  expressions are not
modified under the present experimental conditions
(data not shown). XBP1 splicing was studied using reverse
transcriptase-polymerase chain reaction. cDNA was syn-
thesized as herein reported. Human XBP1 primers (for-
ward: 5'-AAACAGAGTAGCAGCTCAGACTGC-3'; reverse:
5'-TCCTTCTGGGTAGACCTCTGGG AG-3') were designed
to generate cDNA products encompassing the IRE1 cleav-
age site as previously described [28]. The unspliced
(uXBP1) and spliced (sXBP1) mRNAs generate 473- and
447-bp cDNA products, respectively. The amplified prod-
ucts were separated on a 2% agarose gel and visualized
with ethidium bromide staining.
Microarray processing and data analysis
Total RNA was extracted as described above and purified
using the RNeasy mini kit (Qiagen). The quality of total
RNA was assessed using a bioanalyzer (Agilent 2100; Agi-
lent Technologies) and RNA was quantified by using a
ND-1000 Nanodrop spectrophotometer. Ten μg of each
total RNA sample was labelled according to the standard
one-cycle amplification and labelling protocol developed
by Affymetrix (Santa Clara, CA). Labelled cRNA was
hybridized on Affymetrix GeneChip Human U133A 2.0
Arrays containing over 14,500 transcripts. Hybridized
GeneChips were stained, washed (GeneChip Fluidic Sta-
tion 450) and scanned (GeneChip Scanner 3000 7G). Cell
intensity values and probe detection calls were computed
from the raw array data using the Affymetrix GeneChip
Operating Software (GCOS). Further data processing was
performed in the R computing environment http://
www.r-project.org/, version R 2.5.0 for Windows) using
packages from the BioConductor software project http://
www.bioconductor.org/. Variance-stabilizing normaliza-
Table 5: Primer sequences used for qRT-PCR.
Gene name Forward Reverse
DDIT3 5'-CACTCTCCAGATTCCAGTCAG-3' 5'-AGCCGTTCATTCTCTTCAGC-3'
HSPA5 5'-GCACAGACAGATTGACCTATTG-3' 5'-GTAGCACAGGAGCAC-3'
HERPUD1 5'-CTAGATGGCGAGCAGACC-3' 5'-GAGTCAGGTGATCCAGTCC-3'
XBP1 5'-ATGGATTCTGGCGGTATTG-3' 5'-CTGGGTCCTTCTGGGTAG-3'
TRIB3 5'-CGTGATCTCAAGCTGTGTCG-3' 5'-GAGTCCTCCAGGTTCTCC-3'
FAM129A 5'-CCAGGAGTCAGAGGAAGAGAAG-3' 5'-GTTGCCACAGGATTCACCAC-3'
SLC7A11 5'-GGTGGTGTGTTTGCTGTC-3' 5'-GCTGGTAGAGGAGTGTGC-3'
β-ACTIN 5'-CGCCGCCAGCTCACCATG-3' 5'-CACGATGGAGGGGAAGACGG-3'
GAPDH 5'-TCTCTGCTCCTCCTGTTC-3' 5'-GCCCAATACGACCAAATCC-3'BMC Genomics 2009, 10:543 http://www.biomedcentral.com/1471-2164/10/543
Page 14 of 16
(page number not for citation purposes)
tion was applied [62], using the "justvsn" function from
the "vsn" library. Normalized data were then filtered
based on the Affymetrix detection call, so that only probes
that had a Present call in at least one of the arrays were
retained [63]. Data were then imported in the MultiExper-
iment Viewer (MeV) software [64] (version 4.0.01 for
Windows XP), and statistical analysis was performed with
the SAM (Significance Analysis of Microarrays) module
[65,66]. A False Discovery Rate (FDR) of about 10% (i.e.
9.317%) was applied to detect significantly differentially
expressed genes. Microarray data have been deposited in
the NCBI Gene Expression Omnibus (GEO) with Acces-
sion Number GSE16768. Differentially expressed genes
were then specifically examined, based on their Gene
Ontology annotation [67], for their cellular localization
and for their involvement in some biological processes of
interest. GO slim annotations were based on the Generic
GO Term Mapper http://go.princeton.edu/cgi-bin/
GOTermMapper using the Gene Association File
goa_human_hgnc (Generic GO slim).
Immunocytochemistry
For immunofluorescence experiments, SH-SY5Y cells
were cultured on glass slides overnight, fixed in 4% para-
formaldehyde for 10 minutes, washed with PBS two
times, treated with 0.1 M glycine for 5 minutes in PBS and
permeabilized with 0.1% Triton X-100 in PBS for addi-
tional 5 minutes. After washing with PBS and blocking
with 0.2% BSA in PBS, cells were incubated with the anti-
CHOP 1:100 (Santa Cruz Biotechnology) diluted in 0.2%
BSA in PBS for 90 minutes at room temperature. After
washing, cells were incubated with AlexaFluor 594 (Dako
Cytomation)-labelled anti-mouse secondary antibody for
1 h. For nuclear staining, cells were incubated with 1 μg/
mL DAPI for 5 minutes. Cells were washed and mounted
with Vectashield mounting medium (Vector). Images
were collected using a confocal microscope (LEICA TCS
SP2).
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